Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296445862> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4296445862 endingPage "S234" @default.
- W4296445862 startingPage "S234" @default.
- W4296445862 abstract "Background: Normothermic machine perfusion (NMP) is an emerging preservation technique for kidney allografts to reduce post-transplant complications, including interstitial fibrosis and tubular atrophy. This technique could be improved by adding antifibrotic molecules to perfusion solutions. We introduce a novel therapeutic approach, tested in a newly developed fibrosis model, to suppress fibrogenesis entitled Machine perfusion and Organ slices as a Platform for Ex vivo Drug delivery (MOPED). Our approach involves ex vivo perfusion with a blood based perfusate spiked with transforming growth factor beta (TGF-β) —one of the most important cytokines involved in fibrogenesis—and added galunisertib—a potent inhibitor of the TGF-β signalling pathway. Methods: Porcine kidneys were subjected to 30min of warm ischemia, 24h of oxygenated hypothermic machine perfusion (HMP), and 6h of NMP with treatment (control, TFG-β, galunisertib, or TGF-β+galunisertib; n=8). To determine whether effects persisted upon ceasing treatment, precision-cut kidney slices (PCKS) were prepared from respective kidneys and incubated for 48h with treatment continued and discontinued (Figure 1a). Results: Galunisertib supplementation improved the general viability, characterized by an increased oxygen consumption, elevated ATP levels and attenuated tubular dilation and necrosis. No significant differences in renal function, oxidative stress levels, or injury markers were observed. Galunisertib altered inflammation markers by causing a significant increase in gene expression of TNF-α, and a significant decrease of IL-6 after 6h NMP. This was supported by IL-6 protein expression. Continued TGF-β supplementation promoted fibrogenesis as shown by significantly increased mRNA expression of ACTA2, COL1A2, FN-1, SERPINE1, SERPINH1, and TGF-β after 48h of incubation. Continued treatment with galunisertib, however, clearly attenuated the expression of all tested fibrosis-related genes after 48h incubation (Figure 1b-g). Conclusions: Our findings suggest that galunisertib positively affected mitochondrial activity, tissue integrity and expression of fibrogenesis-related genes, and therefore appears to be a promising drug for further research. These findings illustrate the value of targeted drug delivery using isolated organ perfusion for reducing post-transplant complications.This work was funded by the Graduate School of Medical Sciences, and the Groningen Research Institute of Pharmacy, University of Groningen." @default.
- W4296445862 created "2022-09-20" @default.
- W4296445862 creator A5023696538 @default.
- W4296445862 creator A5023853436 @default.
- W4296445862 creator A5071771936 @default.
- W4296445862 creator A5071808540 @default.
- W4296445862 creator A5081305399 @default.
- W4296445862 date "2022-09-01" @default.
- W4296445862 modified "2023-10-04" @default.
- W4296445862 title "315.3: Targeted Delivery of Galunisertib Attenuates Fibrogenesis in an Integrated Ex Vivo Renal Transplant and Fibrosis Model" @default.
- W4296445862 doi "https://doi.org/10.1097/01.tp.0000886584.85217.46" @default.
- W4296445862 hasPublicationYear "2022" @default.
- W4296445862 type Work @default.
- W4296445862 citedByCount "0" @default.
- W4296445862 crossrefType "journal-article" @default.
- W4296445862 hasAuthorship W4296445862A5023696538 @default.
- W4296445862 hasAuthorship W4296445862A5023853436 @default.
- W4296445862 hasAuthorship W4296445862A5071771936 @default.
- W4296445862 hasAuthorship W4296445862A5071808540 @default.
- W4296445862 hasAuthorship W4296445862A5081305399 @default.
- W4296445862 hasBestOaLocation W42964458621 @default.
- W4296445862 hasConcept C126322002 @default.
- W4296445862 hasConcept C142724271 @default.
- W4296445862 hasConcept C146957229 @default.
- W4296445862 hasConcept C150903083 @default.
- W4296445862 hasConcept C207001950 @default.
- W4296445862 hasConcept C26291073 @default.
- W4296445862 hasConcept C2780091579 @default.
- W4296445862 hasConcept C2780559512 @default.
- W4296445862 hasConcept C71924100 @default.
- W4296445862 hasConcept C86803240 @default.
- W4296445862 hasConcept C98274493 @default.
- W4296445862 hasConceptScore W4296445862C126322002 @default.
- W4296445862 hasConceptScore W4296445862C142724271 @default.
- W4296445862 hasConceptScore W4296445862C146957229 @default.
- W4296445862 hasConceptScore W4296445862C150903083 @default.
- W4296445862 hasConceptScore W4296445862C207001950 @default.
- W4296445862 hasConceptScore W4296445862C26291073 @default.
- W4296445862 hasConceptScore W4296445862C2780091579 @default.
- W4296445862 hasConceptScore W4296445862C2780559512 @default.
- W4296445862 hasConceptScore W4296445862C71924100 @default.
- W4296445862 hasConceptScore W4296445862C86803240 @default.
- W4296445862 hasConceptScore W4296445862C98274493 @default.
- W4296445862 hasIssue "9S" @default.
- W4296445862 hasLocation W42964458621 @default.
- W4296445862 hasLocation W42964458622 @default.
- W4296445862 hasLocation W42964458623 @default.
- W4296445862 hasOpenAccess W4296445862 @default.
- W4296445862 hasPrimaryLocation W42964458621 @default.
- W4296445862 hasRelatedWork W2004172311 @default.
- W4296445862 hasRelatedWork W2013765863 @default.
- W4296445862 hasRelatedWork W2084547689 @default.
- W4296445862 hasRelatedWork W2118417242 @default.
- W4296445862 hasRelatedWork W2403234964 @default.
- W4296445862 hasRelatedWork W2463515876 @default.
- W4296445862 hasRelatedWork W2913223560 @default.
- W4296445862 hasRelatedWork W4235616939 @default.
- W4296445862 hasRelatedWork W4361885283 @default.
- W4296445862 hasRelatedWork W4361920767 @default.
- W4296445862 hasVolume "106" @default.
- W4296445862 isParatext "false" @default.
- W4296445862 isRetracted "false" @default.
- W4296445862 workType "article" @default.